The Life Sciences team advised Nimbus Therapeutics on its $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P.
Nimbus Therapeutics is a biotechnology company designing breakthrough medicines through structure-based drug discovery and development.
The funds support the acceleration of Nimbus’ Phase 1 allosteric tyrosine kinase 2 (TYK2) inhibitor into Phase 2 early next year, its hematopoietic progenitor kinase 1 (HPK1) inhibitor into the clinic next year, as well as the advancement of its preclinical portfolio of new medicines.
The Goodwin team was led by William Collins, Gabriela Morales-Rivera, Brittany Morreale, and Karin Yoo.
For more details, read the press release and articles in FierceBiotech and Endpoints.
Nimbus Therapeutics is a biotechnology company designing breakthrough medicines through structure-based drug discovery and development.
The funds support the acceleration of Nimbus’ Phase 1 allosteric tyrosine kinase 2 (TYK2) inhibitor into Phase 2 early next year, its hematopoietic progenitor kinase 1 (HPK1) inhibitor into the clinic next year, as well as the advancement of its preclinical portfolio of new medicines.
The Goodwin team was led by William Collins, Gabriela Morales-Rivera, Brittany Morreale, and Karin Yoo.
For more details, read the press release and articles in FierceBiotech and Endpoints.